Slovakia’s SUKL confirms unavailability of epilepsy drug Rivotril

Pharmaceutical company Roche is withdrawing epilepsy drug Rivotril (Rx) from the Slovak market, the Slovak State Institute for Drug Control said.

The SUKL contacted the marketing authorisation holder (MAH) after receiving a growing number of enquiries from patients and healthcare practictioners regarding the availability of the drug. The manufacturer confirmed that Rivotril 0.5 mg is no longer available in the wholesale distribution chain, while the distribution of Rivotril 2 mg and Rivotril 2.5 mg will be stopped early next year.

The SUKL asked the marketing authorisation holder (MAH) to issue an official statement, which will be published on the regulator’s website, as well as on the websites of various healthcare organisations.